|
|
|
|
Issue 30, December 2007
|
|
|
| |
Dear Readers of HIV@MSD, ,
The end of the year getting closer, the MSD HIV Team would like to thank you for your faithfulness and your kind support during a little more than the last two years.
In 2007, HIV@MSD has shared with you a number of testimonies and experiences that we hope can be applied to your own settings.
We sincerely wish that the worldwide launch of the Blueprint for Business Action against HIV/AIDS will increase the management of HIV/AIDS infected people in the private sector.
For those who have regularly asked us for information on drug developments, we are proud to say that MSD's innovation and commitment towards HIV/AIDS-infected people have resulted in the introduction of new treatments:
- an all HAART Once-a-day single tablet regimen,
- a new drug in an entirely new therapeutic class: the integrase inhibitor
(for more information on these products, visit www.merck.com).
Waiting for a Wonderful Year in 2008, here is a Xmas gift from the Team to YOU! Click here...
|
|
|
|
Our mailing list has been registered with the the French Data Protection Authority.
It contains your first name, family name and email address which shall
be used only to send you this newsletter. In accordance with articles
38 and seq. of the French Data Privacy Law dated January 6, 1978 as
amended, you may access, modify or delete your personal information
upon request. Read our PRIVACY NOTICE for more information.
To remove your address from our mailing list, please UNSUBSCRIBE |
Lettre d'information HIV@MSD en français